Bibliography

Abdelmalek MF, Harrison ME, Gross JB Jr, et al. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. J Clin Gastroenterol 1998;26(2):130-4.

Adinolfi LE, Andreana A, Utili R, et al. HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. American Journal of Gastroenterology 1998;93(11):2162-6.

Adinolfi LE, Utili R, Andreana A, et al. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. Eur J Clin Gastroenterol Hepatol 2000;12(3):299-304.

Ahmed MM, Mutimer DJ, Elias C, et al. A combined management protocol for patients with coagulation disorders infected with hepatitis c virus. Br J Haematol 1996;95(2):383-8.

Aizawa Y, Shibamoto Y, Takagi I, et al. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000;89(1):53-9.

al-Faleh FZ, Sbeih F, al-Karawi M, et al. Treatment of chronic hepatitis C genotype 4 with alpha-interferon in Saudi Arabia: a multicenter study. Hepato-Gastroenterology 1998;45(20):488-91.

Albloushi SS, Murray FE, Callagy G, et al. Changes in liver histopathology in women infected with hepatitis C through contaminated anti-D immunoglobulin injections in Ireland. Eur J Clin Gastroenterol Hepatol 1998;10(1):69-73.

Allory Yves, Charlotte Frederic, Benhamou Yves, et al. Impact of human immunodeficiency virus infection on the histological features of Chronic hepatitis C: a case-control study. Hum Path 2000;31(1):69-74.

Alric L, Duffaut M, Selves J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. Journal of Hepatology 2001;35(2):272-8.

Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine 1999;341(8):556-2.

Anderson FH, Zeng LC, Rock NR, et al. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C. Hepatol Res 2000;18(1):63-71.

Andreone P, Cursaro C, Gramenzi A, et al. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver 1996;16(3):207-10.

Andriulli A, Festa V, Leandro G, et al. Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study. Digestive Diseases and Sciences 2001;46(7):1409-15.

A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28(3):751-5.

Angelico M, Cepparulo M, Barlattani A, et al. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Alimentary Pharmacology and Therapeutics 2000;14(11):1459-67.

Arase Y, Chayama K, Ikeda K, et al. Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C. Hepatol Res 2001;21(1):55-66.

Ariizumi S, Takasaki K, Yamamoto M, et al. Multicentric hepatocellular carcinomas tend to grow in more damaged segments of the liver. Journal of Gastroenterology 2000;35(6):441-4.

Ascione A, De Luca M, Canestrini C, et al. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study. Italian Journal of Gastroenterology and Hepatology 1998;30(5):517-23.

Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. American Journal of Gastroenterology 2000;95(6):1545-50.

Badizadegan K, Jonas MM, Ott MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998;28(5):1416-23.

Banner BF, Barton AL, Cable EE, et al. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Modern Pathology 1995;8(3):232-8.

Bantel H, Lugering A, Poremba C, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001;34(4):758-67.

Baran RL, Oliver JH =3rd, Dodd GD, et al. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996;199:505.

Barbacini IG, Goldoni E, De Sanctis GM, et al. Different reactivity against HCV proteins (RIBA 3) according to progression of liver damage. Panminerva Medica 1998;40(4):269-72.

Barbaro G, Di Lorenzo G, Soldini M, et al. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. American Journal of Gastroenterology 1998;93(12):2445-51. Comment in: Am J Gastroenterol. 1999 Oct;94(10):3087-8.

Barbaro G, Di Lorenzo G, Soldini M, et al. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators. Scandinavian Journal of Gastroenterology 1999;34(9):928-33.

Barbaro G, Di Lorenzo G, Soldini M/Parrotto S, et al. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative andcorrelations with plasmatic and lymphocytic concentrations and with the activity of liver disease. American Journal of Gastroenterology 1996;91(12):2569-73.

Baroni G, Pastorelli A, Manzin A, et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and th1-like response in chronic hepatitis C. Liver 1999;19(3):212-19.

Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001;49(3):423-30.

Bassit La, Da Silva L , Ribeiro-Dos-Santos G, et al. Chronic hepatitis C virus infections in brazilian patients: association with genotypes, clinical parameters and response to long term alphainterferon therapy. Revista Do Instituto De Medicina Tropical De Sao Paulo 1999;41(3):183-9.

Batey RG, Bensoussan A, Fan YY, et al. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. Journal of Gastroenterology and Hepatology 1998;13(3):244-7.

Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. American Journal of Gastroenterology 1998;93(12):2452-6.

Bell H, Hellum K, Harthug S, et al. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha-2a treatment in patients with chronichepatitis C. Scandinavian J Arch Infect Dis 1997;29(1):17-22.

Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999;44(6):874-80.

Bellobuono A, Mondazzi L, Tempini S, et al. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment. European Journal

of Gastroenterology and Hepatology 1997;9(12):1169-77.

Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30(4):1054-58.

Benhamou Y, Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001;34(2):283-7.

Benvegnu L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25(1):211-5.

Berg T, Hoffmann RM, Teuber G, et al. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Liver 2000;20(6):427-36.

Berlin J. Does blinding of readers affect the results of meta-analyses? Lancet 1997;350:185-6.

Bernardinello E, Cavalletto L, Chemello L, et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepato-Gastroenterology 1999;46(30):3216-22.

Bierhoff E, Fischer HP, Willsch E, et al. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Archiv 1997;430(4):271-7.

Biron Christine, Andreani Hubert, Blanc Pierre, et al. Prevalence of antiphospholipid antibodies in patients with chronicliver disease related to alcohol or hepatitis C virus: correlation with liver injury. J Lab Clin Med 1998;131(3):243-50.

Bodenheimer Henry C Jr, Lindsay Karen L, Davis Gary L, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitisc: a multicenter trial. Hepatology 1997;26(2):473-7.

Bonacini M, Groshen S, Yu MC, et al. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. American Journal of Gastroenterology 2001;96(8):2438-41.

Bonino F, Oliveri F, Colombatto P, et al. Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey. Journal of Viral Hepatitis 1997;4(2):79-82.

Bonis PAL, Tong MJ, Blatt LM, et al. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. American Journal of Gastroenterology 1999;94(6):1605-12.

Bonkovsky HL, Stefancyk D, McNeal K, et al. Comparative effects of different doses of ribavirin plus interferon-alpha 2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. Digestive Diseases and Sciences 2001;46(10):2051-9.

Bonkovsky HL, Clifford BD, Smith LJ, et al. High-Dose Interferon-Alpha-2b for Re-Treatment of nonresponders orrelapsing patients with chronic hepatitis C: a controlled randomized trial. Digestive Diseases and Sciences 1996;41(1):149-54.

Bortolotti F, Resti M, Giacchino R, et al. Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. Journal of Pediatrics 1997;130(6):990-3.

Boucher E, Guyader D, Jacquelinet S, et al. Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients. Dig Liver Dis 2000;32(1):29-33.

Boya P, Larrea E, Sola I, et al. Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression. Hepatology 2001;34(5):1041-8.

Bresci G, Parisi G, Bertoni M, et al. High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon. Dig Liver Dis 2000;32(8):703-7.

Bresci G, Parisi G, Metrangolo S, et al. Comparison among different types, dosages and duration of

interferon therapy in chronic hepatitis C. Clin Drug Invest 1998;15(4):271-7.

Brillanti S, Levantesi F, Masi L, et al. Triple antiviral therapy as a new option for patients with interferonnonresponsive chronic hepatitis C. Hepatology 2000;32(3):630-4.

Brouwer JT, Nevens F, Kleter B, et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. Journal of Hepatology 1998;28(6):951-9.

Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997;25(2)259-62.

Brunetto MR, Oliveri F, Koehler M, et al. Effect of interferon-alpha on progression of cirrhosis tohepatocellular carcinoma: A retrospective cohort study. Lancet 1998;351(9115):1535-9.

Bruno R, Debiaggi M, Sacchi P, et al. Daily interferon regimen for chronic hepatitis C: A prospective randomised study. Clinical Drug Investigation 1999;18(1):11-6.

Bruno S, Battezzati Pier M, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. Journal of Hepatology 2001;34(5):748-55.

Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology 1997;25(3):754-8.

Buti M, Olive G, Stalgis C, et al. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C. Digestive Diseases and Sciences 2000;45(4):685-9.

Caballero T, Perez-Milena A, Masseroli M, et al. Liver fibrosis assessment with semiquantitative indexes and imageanalysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. Journal of Hepatology 2001;34(5):740-7.

Cacopardo B, Berger A, Cosentino S, et al. Influence of hepatitis G virus coinfection on the clinical course of chronic hepatitis C. European Journal of Clinical Microbiology & Infectious Diseases 1998;17(10):709-14.

Calleri G, Colombatto P, Gozzelino M, et al. Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial. Ital J Gastroenterol Hepatol 1998;30(2):181-4.

Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology, Dialysis, Transplantation 1999;14(11):2704-9.

Caronia S, Bassendine MF, Barry R, et al. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study. Journal of Hepatology 2001;35(4):512-6.

Carreno V, Martin J, Pardo M, et al. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C. Cytokine 2000;12(2):165-70.

Casaril M, Capra F, Gabrielli GB, et al. Long-term varisations of serum lamini and procollagen-III peptide in chronic HCV hepatitis after alpha-interferon therapy. Ital J Gastroenterol 1996;28(1):15-9.

Casaril M, Stanzial AM, Tognella P, et al. Role of iron load on fibrogenesis in chronic hepatitis C. Hepato-Gastroenterology 2000;47(31):220-5.

Castaldo G, Calcagno G, Sibillo R, et al. Quantitative analysis of aldolase A mRNA in liver discriminates between hepatocellular carcinoma and cirrhosis. Clin Chem 2000;46(7):901-6.

Castro A, Suarez D, Inglada L, et al. Multicenter randomized, controlled study of intramuscular

administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res 1997;17(1):27-30.

Cavalletto L, Chemello L, Donada C, et al. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group. Journal of Hepatology 2000;33(1):128-34.

Cecere A, Romano C, Caiazzo R, et al. Lymphoblastoid alpha-IFN, leukocytic alpha-IFN and natural beta-IFN in the treatment of chronic hepatitis C: a clinical comparison of 150 cases. Hepatology Research 1999;15(3):225-37.

Cedrone A, Covino M, Caturelli E, et al. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepato-Gastroenterology 2000;47(36):1654-8.

Cervello M, Virruso L, Lipani G, et al. Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2000;126(6):345-51.

Cesaro S, Petris MG, Rossetti F, et al. Chronic hepatitis C virus infection after treatment for pediatric malignancy. Blood 1997;90(3):1315-20.

Chan T M, Wu P C, Lau J Y N, et al. Interferon Treatment for Hepatitis C Virus Infection in Patients Onhaemodialysis. Nephrol Dial Transplant 1997;12(7):1414-9.

Chapman BA, Stace NH, Edgar CL, et al. Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon. New Zealand Medical Journal 2001;114(1128):103-4.

Chayama K, Tsubota A, Kobayashi M, et al. A pilot study of corticosteroid priming for lymphoblastoid interferonalfa in patients with chronic hepatitis C. Hepatology 1996;23(5):953-7.

Chemello L, Cavalletto L, Bernardinello E, et al. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group. Journal of Viral Hepatitis 1999;6(4):321-7.

Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. Annals of Internal Medicine 1996;124(12):1058-60.

Chemello L, Cavalletto L, Donada C, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997;113(5):1654-9.

Cheng SJ, Bonis PA, Lau J, et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33(1):231-40.

Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85(10):2132-7.

Chiba T, Matsuzaki Y, Abei M, et al. The role of previous hepatitis-B virus-infection and heavy smoking in hepatitis-C virus-related hepatocellular-carcinoma. American Journal of Gastroenterology 1996;91(6):1195-203.

Cho SG, Kim MY, Kim HJ, et al. Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology 2001;221(3):740-6.

Choi Y, Putti T, Win K, et al. Correlation of viral RNA, alanine aminotransferase, and histopathology in hepatitis C virus-associated hepatitis. Molecular Diagnosis 1999;4(3):251-4.

Chu CW, Hwang SJ, Luo JC, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001;32(3):240-4.

Colombo M, Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. New England Journal of Medicine 1991;325:675.

Conferences - Management of Hepatitis C 2002. 2001; accessed 2002. Web Page. Available at: http://odp.od.nih.gov/consensus/news/upcoming/hepc/hepc_info.htm

Conry-Cantilena C. Hepatitis C virus diagnostics: technology, clinical applications and impacts. Trends in Biotechnology 1997;15(2):71-6.

Cotler SJ, Taylor SL, Gretch DR, et al. Hyperbilirubinemia and cholestatic liver injury in hepatitis C-infected liver transplant recipients. American Journal of Gastroenterology 2000;95(3):753-9.

Cottone M, Turri M, Caltagirone M, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. Journal of Hepatology 1994;21:1029-34.

Craxi A, Di Marco V, Iacono OL, et al. Transfusion-associated chronic hepatitis C: alpha-N-1 interferon for 6 vs. 12 months. Journal of Hepatology 1996;24(5):539-46.

Cromie SL, Jenkins PJ, Bowden DS, et al. Chronic hepatitis C: effect of alcohol on hepatitic activity and viraltitre. Journal of Hepatology 1996;25(6):821-6.

Crosignani A, Budillon G, Cimino L, et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepato-Gastroenterology 1998;45(23):1624-9.

Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 2001;285(2):193-9.

Curley SA, Izzo F, Gallipoli A, et al. Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Annals of Surgery 1995;222(3):375-80; discussion 380-3.

Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in hemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-31.

Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. New England Journal of Medicine 2001;345(11):825-6.

de Lucas S, Bartolome J, Rodriguez-Inigo E, et al. Distribution of hepatitis C virus infection in liver biopsies from children and adults with chronic hepatitis C. Journal of Medical Virology 2001;64(1):1-5.

Degos F, Daurat V, Chevret S, et al. Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group. Journal of Hepatology 1998;29(2):224-32. Comment in: ACP J Club. 1999 Mar-Apr;130(2):37.

Demirhan B, Boyacioglu S, Kart H, et al. Histopathological features of hepatitis C virus infection in patients with chronic renal failure and renal transplantation. Transplantation Proceedings 1996;28(4):2328-30.

Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a

multicenter, prospective, randomized, controlled trial. Hepatology 2000;32(1):135-8.

Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, et al. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001;33(3):704-7.

Di Costanzo GG, Ascione A, Lanza AG, et al. Resistance to alpha interferon therapy in HCV chronic liver disease: role of hepatic fibrosis. Ital J Gastroenterol 1996;28(3):140-6.

Di Marco V, Lo Iacono O, Camma C, et al. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. Journal of Medical Virology 1997;51(1):17-24.

Diago M, Suarez D, Garcia-Villarreal L, et al. Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C. Journal of Medical Virology 2001;64(4):460-5.

Dietrich CF, Stryjek-Kaminska D, Teuber G, et al. Perihepatic lymph nodes as a marker of antiviral response in patients with chronic hepatitis C infection. AJR. American Journal of Roentgenology 2000;174(3):699-704.

DiMarco V, Almasio P, Vaccaro A, et al. Combined treatment of relapse of chronic hepatitis C with high-dose a(2)b interferon plus ribavirin for 6 or 12 months. Journal of Hepatology 2000;33(3):456-62.

Donada C, Crucitti A, Donadon V, et al. Interferon alpha and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 1998;92(8):2983-4.

Duchatelle V, Marcellin P, Giostra E, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. Journal of Hepatology 1998;29(1):20-8.

Dusheiko G, Main J, Thomas H, et al. Ribavarin treatment for patients with chronic hepatitis-C - results of a placebo-controlled study. Journal of Hepatology 1996;25(5):591-8.

Dutta U, Byth K, Kench J, et al. Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study. Aust N Z J Med 1999;29(3):300-7.

Dutta U, Kench J, Byth K, et al. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum Pathol 1998;29(11):1279-84.

EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. Journal of Hepatology 1999;30(5):956-61.

Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998;351(9115):1535-9.

el-Zayadi A, Selim O, Haddad S, et al. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital J Gastroenterol and Hepatology 1999;31(6):472-5.

Enriquez J, Gallego A, Torras X, et al. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. Journal of Viral Hepatitis 2000;7(6):403-8.

Everson GT, Jensen DM, Craig JR, et al. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology 1999;30(1):271-6.

Fabbri C, Marchetto S, Pezzoli A, et al. Efficacy of ursodeoxycholic acid in association with alpha-

interferon for chronic hepatitis C in alpha-interferon non-responder patients. European Journal of Gastroenterology and Hepatology 2000;12(5):511-5.

Fabris P, Marranconi F, Bozzola L, et al. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN. Journal of Gastroenterology 1999;34(3):345-50.

Fabris P, Tositti G, Negro F, et al. Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients. Alimentary Pharmacology and Therapeutics 1999;13(10):1329-34.

Fanning L, Kenny E, Sheehan M, et al. Viral load and clinicopathological features of chronic hepatitis C (1b)in a homogeneous patient population. Hepatology 1999;29(3):904-7.

Farrell GC, Bacon BR, Goldin RD. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology 1998;27(4):1121-7.

Farrell GC, Bacon BR, Goldin RD, et al. Lymphoblastoid interferon alfa-N1 Improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Hepatology 1998;27(4):1121-7.

Fasani P, Sangiovanni A, DeFazio C, et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999;29(6):1704-7.

Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. Journal of Hepatology 1997;27(1):201-5.

Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112(2):463-72.

Fayyazi A, Schott P, Hartmann H, et al. Clinical, biochemical, and histological changes in hepatitis C virus infection-associated cryoglobulinemia. Z Gastroenterol 1997;35(10):921-8.

Felipe M, Silva AE, Lopes EP, et al. A prospective and randomized study using ribavirin as monotherapy for the treatment of naive patients with chronic hepatitis C. Braz J Infect Dis 2000;4(4):183-91.

Ferenci P, Brunner H, Nachbaur K, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001;34(5):1006-11.

Ferenci P, Stauber R, Propst A, et al. Dose increase augments response rate to interferon-alpha in chronic hepatitis C. Digestive Diseases and Sciences 1996;41(12 Suppl):103S-8S.

Ferenci P, Stauber R, Steindl-Munda P, et al. Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Eur J Clin Gastroenterol Hepatol 2001a;13(6):699-705.

Fernandez I, Castellano G, Domingo MJ, et al. Influence oc viral genotype and level of viermia on the severity of liver-injury and the response to interferon therapy in Spanish patients with chronic-C infection. Scand J Gastroenterol 1997;32(1):70-6.

Fernandez JL, Rendo P, delPino N, et al. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal

aminotransferase levels. Journal of Viral Hepatitis 1997;4(2):113-9.

Fong TL, Han SH, Tsai NC, et al. A pilot randomized controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. Journal of Hepatology 1998;28(3):369-74.

Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001;32(9):904-9.

Fontana RJ, Israel J, LeClair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000;31(3):730-6.

Forns X, Ampurdanes S, Sanchez-Tapias JM, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. Journal of Hepatology 2001;35(2):265-71.

Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47(9):1696-700.

Foster GR, Goldin RD, Main J, et al. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 1997;315(7106):453-8.

Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809-16.

Fried MW, Shiffman M, Sterling RK, et al. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. American Journal of Gastroenterology 2000;95(11):3225-9.

Fried MW, Shiffman ML, Reddy RK, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled multicenter study. Gastroenterology 2001;120(2 Suppl):A289.

Friedlander L, Van Thiel DH, Faruki H, et al. New approach to HCV treatment: recognition of disease process as systemic viral infection rather than as liver disease. Digestive Diseases and Sciences 1996;41(8):1678-81.

Fujisawa T, Komatsu H, Inui A, et al. Spontaneous remission of chronic hepatitis C in children. Eur J Pediatr 1997;156(10):773-6.

Fujiwara K, Mochida S, Matsuo S, et al. Randomized control trial of interferon-beta injections at 12-h intervals as a therapy for chronic hepatitis C. Hepatology Research 1998;12(3):240-51.

Fukuda Y, Nakano I, Katano Y, et al. Assessment and treatment of liver disease in Japanese haemophilia patients. Haemophilia 1998;4(4):595-600.

Fukuzaki T, Kawata S, Imai Y, et al. Changes in serum hepatic fibrosis markers in biochemical responders to interferon therapy for chronic hepatitis C. Hepatology Research 2000;17(2):156-66.

Furusyo N, Hayashi J, Kanamoto-Tanaka Y, et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Digestive Diseases and Sciences 2000;45(11):2221-8.

Gabrielli GB, Capra F, Casaril M, et al. Serum laminin and type III procollagen in chronic hepatitis C: diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 1997;265(1):21-31.

Gaeta GB, DiVirgilio D, Russo G, et al. Human leucocyte interferon-alpha in chronic hepatitis C

resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial. Journal of Viral Hepatitis 1997;4(3):209-14.

Gaeta GB, Stornaiuolo G, Stanzione M, et al. Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. Journal of Viral Hepatitis 2001;8(4):284-6.

Ganne-Carrie N, Chastang C, Uzzan B, et al. Predictive value of serum sex hormone binding globulin for the occurrence of hepatocellular carcinoma in male patients with cirrhosis. Journal of Hepatology 1997;26(1):96-102.

Ganne-Carrie N, Christidis C, Chastang C, et al. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study. Gut 2000;46(2):277-82.

Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence a review of the evidence. JAMA 1999;281(14)1318-25.

Garson JA, Uhnoo I, Whitby K, et al. Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C. Journal of Viral Hepatitis 1997;4(5):325-31.

Gattoni A, Romano C, Cecere A, et al. Serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) as a potential marker of disease activity and remission in patients with chronic hepatitis C. Panminerva Medica 1997;39(4):256-62.

Gentilini P, Laffi G, Lavilla G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. American Journal of Gastroenterology 1997;92(1):66-72.

Gervais A, Martinot M, Boyer N, et al. Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment. Journal of Hepatology 2001;35(3):399-405.

Gholson CF, Morgan K, Catinis G, et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. American Journal of Gastroenterology 1997;92(10):1788-92. Comment in: Am J Gastroenterol. 1997 Oct;92(10):1775-7.

Giannini E, Arzani L, Borro P, et al. Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? Hepatogastroenterology 2000;47(35):1395-8.

Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST ALT ratio. Digestive Diseases and Sciences 1999;44(6):1249-53.

Giannini E, Caglieris S, Ceppa P, et al. Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. Eur J Clin Gastroenterol Hepatol 2001;13(2):137-41.

Gluck T, Seelig R, Dette S, et al. Parameters predicting responses to alpha-interferon treatment in chronic hepatitis C. Hepatogastroenterology 1997;44(14):484-91.

Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clinical Pharmacology and Therapeutics 2000;68(5):556-67.

Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;32(3):647-53.

Goldstein NS, Blue DE, Hankin R, et al. Serum alpha-fetoprotein levels in patients with chronic

hepatitis C - relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol 1999;111(6):811-6.

Gonzalez-Peralta RP, Qian K, She JY, et al. Clinical implications of viral quasi-species heterogeneity in chronic hepatitis C. Journal of Medical Virology 1996;49(3):242-7.

Gordon SC, Fang JW, Silverman AL, et al. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000;32(2):400-4.

Graf J, Toriyama K, Itakura H. A clinico-pathological study of 163 untreated cases of chronic hepatitis C. Revista da Sociedade Brasileira de Medicina Tropical 1996;29(1):21-5.

Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. 2001;33:562-9.

Grant PR, Black A, Garcia N, et al. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. Journal of Medical Virology 2000;61(4):439-42.

Guechot J, Laudat A, Loria A, et al. Diagnostic Accuracy of Hyaluronan and Type Iii Procollagenamino-Terminal Peptide Serum Assays as Markers of Liver Fibrosis Inchronic Viral Hepatitis C Evaluated by Roc Curve Analysis. Clin Chem 1996;42(4):558-63.

Guechot J, Poupon RE, Giral P, et al. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. Journal of Hepatology 1994;20(3):388-93.

Guechot J, Serfaty L, Bonnand A-M, et al. Prognostic Value of Serum Hyaluronan in Patients With Compensated Hcvcirrhosis. Journal of Hepatology 2000;32(3):447-52.

Guido M, Rugge M, Jara P, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998;115(6):1525-9.

Guilera M, Forns X, Torras X, et al. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. Journal of Hepatology 2000;33(1):135-41.

Gursoy M, Bilezikci B, Colak T, et al. Histologic outcome of hepatitis C virus infection in renal transplant recipients and the effect of pretransplantation interferon treatment. Transplantation Proceedings 2000;32(3):558-60.

Haber MM, West AB, Haber AD, et al. Relationship of aminotransferases to liver histological status in chronic hepatitis C. American Journal of Gastroenterology 1995;90(8):1250-7.

Hadziyannis AS, Papaioannou C, Spanou F, et al. Induction interferon therapy in naive patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Alimentary Pharmacology and Therapeutics 2001;15(4):551-7.

Hagiwara H, Hayashi N, Mita E, et al. Influence of transfusion-transmitted virus infection on the clinical features and response to interferon therapy in Japanese patients with chronic hepatitis C. Journal of Viral Hepatitis 1999;6(6):463-9.

Hanley JP, Jarvis LM, Andrew J, et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs–influence of virus load, genotype, and liver pathology on response. Blood 1996;87(5):1704-9.

Harris HE, Ramsay ME, Andrews N, Eldridge KP. Clinical course of hepatitis C virus during the first

decade of infection: cohort study. BMJ 2002;324:1-6.

Hashimoto O, Ueno T, Sata M, et al. Long-term improvement of hepatic fibrosis in chronic hepatitis C treated with interferon-alpha. Hepatology Research 1998;10(3):200-16.

Hayashi J, Furusyo N, Ariyama I, et al. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 2000;181(5):1523-7.

Haydon GH, Jalan R, AlaKorpela M, et al. Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. Journal of Viral Hepatitis 1998;5(4):255-64.

Healey CJ, Chapman RW, Fleming KA. Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. Gut 1995;37(2):274-8.

Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon . Hepatology 1998;27(4):1136-43.

Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine 2000;343(23):1673-80.

Hedin K, Babic A, Fryden A. Liver guide for monitoring of chronic hepatitis C. Proceedings / Amia Symposium 2000;340-3.

Heintges T, Mohr L, Hensel F, et al. Value of liver biopsy prior to interferon therapy for chronic viral hepatitis. Digestive Diseases and Sciences 1998;43(7):1562-5.

Helbling B, Stamenic I, Viani F, et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 2002;35(2):447-54.

Herve S, Savoye G, Riachi G, et al. Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity? Eur J Clin Gastroenterol Hepatol 2001;13(5):495-500.

Hirata M, Akbar S M F, Horiike N, et al. Noninvasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus. Eur J Clin Invest 2001;31(6):528-35.

Hopf U, Berg T, Koenig V, et al. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes. Journal of Hepatology 1996;24(SUPPL. 2):67-73.

Horiike N, Fujisawa T, Michitaka K, et al. The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C. Oncology Reports 1998;5(5):1171-4.

Hoshida Y, Ikeda K, Kobayashi M, et al. Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis. Journal of Hepatology 1999;31(5):860-6.

Hwang S-J, Luo J-C, Chu C-W, et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalenceand clinical correlation. Journal of Gastroenterology and Hepatology 2001;16(2):190-5.

Hwang SJ, Lee SD, Chan CY, et al. A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C. American Journal of Gastroenterology 1999;94(9):2496-500.

Ideo G, Bellobuono A, Tempini S, et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. European Journal of Gastroenterology and Hepatology 1999;11(11):1203-7.

Iijima A, Tanaka E, Kobayashi M, et al. Relationship between histological prognosis of chronic hepatitis C and amount of hepatitis C virus core protein in serum. Journal of Gastroenterology and Hepatology 2000;15(3):311-9.

Iijima Y, Kato T, Miyakawa H, et al. Effect of interferon therapy on Japanese chronic hepatitis C virus patients with anti-liver/kidney microsome autoantibody type 1. Journal of Gastroenterology and Hepatology 2001;16(7):782-8.

Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32(2):228-32.

Ikeda K, Saitoh S, Kobayashi M, et al. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. Journal of Gastroenterology and Hepatology 2001;16(4):406-15.

Ikeda K, Saitoh S, Kobayashi M, et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatology Research 2000;18(3):252-66.

Ikeda K, Satoshi S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;12:47-53.

Ikura Y, Morimoto H, Johmura H, et al. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. American Journal of Gastroenterology 1996;91(7):1367-73.

Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infectiona prospective study. Lancet 2001;3571069-75.

Imperiale TF, Said AT, Cummings OW, et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. American Journal of Gastroenterology 2000;95(9):2328-32.

Inoue A, Tsukuma H, Oshima A, et al. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis. Journal of Epidemiology 2000;10(4):234-40.

Ishibashi K, Kashiwagi T, Ito A, et al. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Hepatology 1996;24(1):27-31.

Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. American Journal of Gastroenterology 2000;95(4):1036-40.

Izumi N, Enomoto N, Uchihara M, et al. Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Digestive Diseases and Sciences 1996;41(5):989-94.

Izumi N, Kumada H, Hashimoto N, et al. Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study. Digestive Diseases and Sciences 2001;46(3):516-23.

Izzo F, Cremona F, Delrio P, et al. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein. Annals of Surgical Oncology 1999;6(2):178-85.

Izzo F, Cremona F, Ruffolo F, et al. Outcome of 67 patients with hepatocellular cancer detected during

screening of 1125 patients with chronic hepatitis. Annals of Surgery 1998;227(4):513-8.

Izzo F, Curley S, Maio P, et al. Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis-C virus liver-injury and development of hepatocellular cancer. Surgery 1996;120(1):100-5.

Jamal MM, Soni A, Quinn PG, et al. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999;30(6):1307-11.

Jarmay K, Gallai M, Karacsony G, et al. Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alfa-2b treatment. Journal of Hepatology 2000;32(6):993-1002.

Jeffers LJ, Coelho-Little ME, Cheinquer H, et al. Procollagen-III peptide and chronic viral C hepatitis. American Journal of Gastroenterology 1995;90(9):1437-40.

Jenkins PJ, Cromie SL, Bowden DS, et al. Chronic hepatitis-C and interferon-alfa therapy - predictors of long term response. Med J Aust 1996;164(3):150-2.

Johnson PJ, Leung N, Cheng P, et al. 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer 1997;75(2):236-40.

Kagawa T, Hosoi K, Takashimizu S, et al. Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C. American Journal of Gastroenterology 1998;93(2):192-6.

Kage M, Fujisawa T, Shiraki K, et al. Pathology of chronic hepatitis C in children. Hepatology 1997;26(3):771-5.

Kage M, Shimamatu K, Nakashima E, et al. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology 1997;25(4):1028-31.

Kageyama F, Kobayashi Y, Murohisa G, et al. Failure to respond to interferon-alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C. Biological Trace Element Research 1998;64(1-3):185-96.

Kaji K, Nakanuma Y, Harada K-I, et al. Hemosiderin deposition in portal endothelial cells is a histologic marker predicting poor response to interferon-alpha therapy in chronic hepatitis. Pathol Int 1997;47(6):347-52.

Kakizaki S, Takagi H, Ichikawa T, et al. Histological change after interferon therapy in chronic hepatitis C in view of iron deposition in the liver. Biological Trace Element Research 2000;73(2):151-62.

Kakumu S, Aiyama T, Okumura A, et al. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. Journal of Gastroenterology and Hepatology 1997;12(6):468-72.

Kakumu S, Okumura A, Ishikawa T, et al. Serum levels of Il-10, Il-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clinical and Experimental Immunology 1997;109(3):458-63.

Kameda Y, Asakawa H, Shimomura S, et al. Laparoscopic prediction of hepatocellular carcinoma in cirrhosis patients. Journal of Gastroenterology and Hepatology 1997;12(8):576-81.

Kao JH, Chen PJ, Lai MY, et al. Efficacy of consensus interferon in the treatment of chronic hepatitis C. Journal of Gastroenterology and Hepatology 2000;15(12):1418-23.

Kao JH, Lai MY, Chen PJ, et al. Serum hepatitis-C virus titers in the progression of type-C chronic liver-disease - with special emphasis on patients with type 1B infection. J Clin Gastroenterol 1996;23(4):280-3.

Kaplanski G, Farnarier C, Payan M-J, et al. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C: correlation with cytokine concentrations and liver inflammation and fibrosis. Digestive Diseases and Sciences 1997;42(11):2277-84.

Karim A, Ahmed S, Khan A, et al. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. American Journal of the Medical Sciences 2001;322(4):233-5.

Kasahara A, Hayashi N, Mochizuki K, et al. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group. Journal of Viral Hepatitis 2000;7(5):343-51.

Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C: relationship to interferon response. Journal of Hepatology 1997;26(3):574-83.

Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27(5):1394-402.

Kaserer K, Fiedler R, Steindl P, et al. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology 1998;32(5):454-61.

Kato J, Kobune M, Nakamura T, et al. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Research 2001;61(24):8697-702.

Keeffe EB, Dusheiko GM, James SP, et al. Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group. Cytokines, Cellular and Molecular Therapy 1999;5(4):207-10.

Keeffe EB, Dusheiko GM, Tong MJ, et al. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group. Cytokines, Cellular and Molecular Therapy 1999;5(4):211-6.

Khalili M, Denham C, Perrillo R. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology 2000;95(5):1284-9.

Kiso S, Kawata S, Tamura S, et al. Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial. Journal of Gastroenterology 1997;32(1):56-62.

Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001;323:1151-5.

Kliem V, Van Den Hoff U, Brunkhorst R, et al. The long-term course of hepatitis C after kidney transplantation. Transplantation 1996;62(10):1417-21.

Kobayashi M, Ikeda K, Akuta N, et al. Relationship between five-year histological outcome and serial changes in serum alanine aminotransferase in patients with biochemical and virological relapse after interferon treatment for chronic hepatitis C. Intervirology 2000;43(3):174-9.

Kobayashi M, Tanaka E, Sodeyama T, et al. The natural course of chronic hepatitis-C - a

comparison between patients with genotype-1 and genotype-2 hepatitis-C viruses. Hepatology 1996;23(4):695-9.

Komatsu M, Ishii T, Ono T, et al. Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration. Canadian Journal of Gastroenterology 1997;11(6):507-11.

Komatsu M, Ishii T, Ono T, et al. A dose-dependent controlled trial of human lymphoblastoid interferon alpha for genotype 1b chronic hepatitis C associated with high HCV-RNA levels. Hepatology Research 1997;7(2):105-12.

Komatsu M, Ono T, Nakajima K, et al. A multicentre randomized controlled trial of recombinant interferon-alpha-2a in the treatment of patients with chronic hepatitis C. Canadian Journal of Gastroenterology 1997;11(7):579-82.

Komine F, Shimojima M, Moriyama M, et al. Telomerase activity of needle-biopsied liver samples: its usefulness for diagnosis and judgment of efficacy of treatment of small hepatocellular carcinoma. Journal of Hepatology 2000;32(2):235-41.

Kondo M, Tanaka K, Ikeda M, et al. Hepatic HCV-RNA as a predictor of outcome after interferon therapy in patients with chronic hepatitis-C. Journal of Gastroenterology and Hepatology 1996;11(3):236-40.

Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C Virus-related hepatocellular carcinoma: a randomized, controlled trial. Annals of Internal Medicine 2001;134(10):963-7.

Kubo S, Yamamoto T, Ikebe T, et al. Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C. Japanese Journal of Cancer Research 1999;90(10):1076-80.

Kumada T, Nakana S, Takeda I, et al. Long-term administration of natural interferon-alpha in patients with chronic hepatitis-C - relationship to serum RNA concentration, HCV-RNA genotypes, histological-changes and hepatitis-C virus. Journal of Gastroenterology and Hepatology 1996;11(2):159-65.

Laghi V, Toccaceli F, Rosati S, et al. Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C. Hepatogastroenterology 1997;44(16):1182-6.

Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001;15(16):2149-55.

Larcos G, Sorokopud H, Berry G, et al. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR. American Journal of Roentgenology 1998;171(2):433-5.

Laursen AL, Scheibel E, Ingerslev J, et al. Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment. Haemophilia 1998;4(1):25-32.

Le Guen B, Squadrito G, Nalpas B, et al. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology 1997;25(5):1250-4.

Lee DH, Jamal H, Regenstein FG, et al. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Digestive Diseases and Sciences 1997;42(1):186-91.

Leroy V, De Traversay C, Barnoud R, et al. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-

responders to interferon alpha. Journal of Hepatology 2001;35(1):120-6.

Lesens O, Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999;179:1254-8.

Lethagen S, Widell A, Berntorp E, et al. Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or Vonwillebrand disease. Br J Haematol 2001;113(1):87-93.

Leto G, Tumminello FM, Pizzolanti G, et al. Lysosomal CA thepsin-B and CA thepsin-L and stefin-A blood-levels in patients with hepatocellular-carconoma and or liver-cirrhosis - potential clinical implications. Oncology 1997;54(1):79-83.

Libbrecht L, Craninx M, Nevens F, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001;39(1):66-73.

Lichtinghagen R, Huegel O, Seifert T, et al. Expression of matrix metalloproteinase-2 and-9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 2000;46(2):183-92.

Lichtinghagen R, Michels D, Haberkorn CI, et al. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. Journal of Hepatology 2001;34(2):239-47.

Lichtinghagen R, Steinmetz C, Pehle B, et al. Matrix metalloproteinases in liver and serum in chronic active hepatitis C and HCV-induced cirrhosis. Hepatology Research 1999;14(2):119-34.

Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996;24(5):1034-40.

Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34(2):395-403.

Lirussi F, Beccarello A, Bortolato L, et al. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver 1999;19(5):381-8.

Lo Iacono O, Garcia-Monzon C, Almasio P, et al. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. Alimentary Pharmacology and Therapeutics 1998;12(11):1091-9.

Loguercio C, Caporaso N, Tuccillo C, et al. Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy? Journal of Hepatology 1998;28(3):390-5.

Look MP, Gerard A, Rao GS, et al. Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial. Antiviral Research 1999;43(2):113-22.

Lopez-Labrador F-X, Ampurdanes S, Gimenez-Barcons M, et al. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b interferon. Hepatology 1999;29(3):897-903.

Luo JC, Hwang SJ, Lai CR, et al. Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan. Journal of

Gastroenterology and Hepatology 1998;13(7):685-90.

Magrin S, Craxi A, Fabiano C, et al. HCV viremia is more important than genotype as a predictor of response to interferon in Sicily (Southern Italy). Journal of Hepatology 1996;25(5):583-90.

Makino Y, Shiraki K, Sugimoto K, et al. Histological features of cirrhosis with hepatitis C virus for prediction of hepatocellular carcinoma development; a prospective study. Anticancer Research 2000;20(5C):3709-15.

Makita O, Yamashita Y, Arakawa A, et al. Diagnostic accuracy of helical CT arterial portography and CT hepatic arteriography for hypervascular hepatocellular carcinoma in chronic liver damage. An ROC analysis. Acta Radiologica 2000;41(5):464-9.

Makris M, Preston FE, Rosendaal FR, et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996;94(4):746-52.

Malaguarnera M, Di Fazio I, Ferlito L, et al. Increase of serum beta2-microglobulin in patients affected by HCV correlated hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 2000;12(8):937-9.

Malaguarnera M, Di Fazio I, Ferlito L, et al. A comparison of four types of interferon alpha in the treatment of chronic hepatitis C. Current Therapeutic Research 1998;59(1):48-59.

Manesis EK, Papaioannou C, Gioustozi A, et al. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology 1997;26(3):734-9.

Mangia A, Minerva N, Annese M, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001a;33(4):989-93.

Mangia A, Villani MR, Minerva N, et al. Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: a randomized controlled trial. Journal of Hepatology 2001;34(3):441-6.

Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65.

Marco VD, Almasio P, Vaccaro A, et al. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. Journal of Hepatology 2000;33(3):456-62.

Martin-Vivaldi R, Nogueras F, Gonzalez A, et al. Response of chronic hepatitis C to interferon-alpha treatment and relationship with iron metabolism. Revista Espanola De Enfermedades Digestivas 1997;89(7):527-30.

Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis c in injection drug users: a long term retrospective cohort study. Hepatology 2001;34(6):1193-9.

Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001;34(5):1000-5.

Marui A, Fukuda Y, Koyama Y, et al. Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular vell adhesion molecular-1 in liver disease, and their changes by treatment with interferon. J Int Med Res 1996;24(3):258-65.

Matsumura H, Moriyama M, Goto I, et al. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C - a study

of 527 patients at one establishment. Journal of Viral Hepatitis 2000;7(4):268-75.

Mazzaro C, Panarello G, Carniello S, et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 2000;32(8):708-15.

Mazzella G, Accogli E, Sottili S, et al. Alpha-interferon treatment may prevent hepatocellular-carcinoma in HCV-related liver cirrhosis. Journal of Hepatology 1996;24(2):141-7.

McCormick SE, Goodman ZD, Maydonovitch CL, et al. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. American Journal of Gastroenterology 1996;91(8):1516-22.

McHutchison JG, Blatt LM, de Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Journal of Gastroenterology and Hepatology 2000a;15(8):945-51.

McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339(21)1485-92.

McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Seminars in Liver Disease 1999;19 Suppl 1:57-65.

McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119(5):1317-23.

McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. Journal of Hepatology 2001;34(1):140-7.

McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990;150(5)1051-4.

Meijer K, Haagsma EB, Kok T, et al. Natural history of hepatitis C in HIV-negative patients with congenital coagulation disorders. Journal of Hepatology 1999;31(3):400-6.

Michielsen PP, Hauben EI, Ramon AM, et al. Serum aminotransferase levels and histological disease in chronic hepatitis C. Acta Gastro-Enterologica Belgica 1997;60(1):11-4.

Mihm S, Fayyazi A, Hartmann H, et al. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997;25(3):735-9.

Min AD, Jones JL, Esposito S, et al. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. American Journal of Gastroenterology 2001;96(4):1143-9.

Mitsuda A, Suou T, Ikuta Y, et al. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C. Journal of Hepatology 2000;32(4):666-72.

Mizokami M, Orioto E, Gibo Y, et al. Genotype, serum level of hepatitis-C virus-RNA and liver histology as predictors of response to interferon-alpha 2A therapy in Japanese patients with chronic hepatitis-C. Liver 1996;16(1):23-7.

Mohan KVK, Murugavel KG, Rajanikanth, et al. Diagnosis of hepatitis C virus infection by ELISA, RIBA and RT-PCR: a comparative evaluation. Indian J Gastroenterol 1999;18(2):73-5.

Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK Health Regional Population of 5.12 million. Gut 2001;48(5):707-13.

Montalto G, Giannitrapani L, Soresi M, et al. Circulating E-selectin levels in chronic hepatitis C patients with normal or elevated transaminase before and after alpha-interferon treatment. Inflammation 2001;25(2):101-8.

Montalto G, Soresi M, Carroccio A, et al. Comparative responses to three different types of interferon-alpha in patients with chronic hepatitis C. Current Medical Research and Opinion 1998;14(4):235-41.

Montalto G, Zignego AL, Ruggeri MI, et al. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases. Digestive Diseases and Sciences 1997;42(8):1703-7.

Monteverde A, Ballare M, Pileri S. Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia. Springer Semin Immunopath 1997;19(1):99-110.

Montorsi M, Santambrogio R, Bianchi P, et al. Laparoscopy with laparoscopic ultrasound for pretreatment staging of hepatocellular carcinoma: a prospective study. J Gastrointest Surg 2001;5(3):312-5.

Mori H, Yabu K, Yoshizawa K, et al. Lymphocyte proliferative responses to recombinant hepatitis-C virus-antigens in patients with chronic hepatitis-C. Journal of Gastroenterology and Hepatology 1996;11(8):697-704.

Morisco F, Marmo R, Iasevoli P, et al. Clinical outcome of chronic hepatitis C in patients treated with interferon: comparison between responders and non-responders. Ital J Gastroenterol and Hepatology 1999;31(6):454-8.

Morisco F, Mazziotti G, Rotondi M, et al. Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. Dig Liver Dis 2001;33(3):247-53.

Morita K, Tanaka K, Saito S, et al. Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. Journal of Medical Virology 1999;58(4):359-65.

Moussa YI, Plevris JN, Hayes PC. Plasma nitrites/nitrates in HCV infection and hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 2000;12(2):159-63.

Munoz AE, Levi D, Podesta A, et al. Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial. Gut 2000;46(3):427-31.

Murakami C, Hino K, Korenaga M, et al. Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection. J Clin Gastroenterol 1999;28(2):148-52.

Murawaki Y, Ikuta Y, Okamoto K, et al. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. Journal of Gastroenterology 2001a;36(6):399-406.

Murawaki Y, Koda M, Okamoto K, et al. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 2001;16(7):777-81.

Murawaki Y, Yamada S, Ikuta Y, et al. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. Journal of Hepatology 1999;30(6):1090-8.

Nagai T, Murota M, Nishioka M, et al. Elevation of cytokeratin 19 fragment in serum in patients with hepatoma: its clinical significance. European Journal of Gastroenterology and Hepatology 2001;13(2):157-61.

Nakamura H, Ito H, Kimura Y, et al. The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: a multicenter randomized trial. Hepatogastroenterology 1998;45(22):1045-55.

Nakamura H, Ito H, Ogawa H, et al. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Hepatogastroenterology 1999;46(26):1131-9.

Nakashima E, Kage M, Fujisawa T, et al. Serum hyaluronate level correlates to the degree of liver fibrosis in pediatric liver diseases. Hepatology Research 1999;16(1):59-67.

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(3 Suppl 1):2S-10S.

Nelson DR, Lauwers GY, Lau JYN, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000;118(4):655-60.

Neri S, Ierna D, Antoci S, et al. Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Medica 2000;42(3):187-92.

Neuman MG, Benhamou JP, Malkiewicz IM, et al. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clinical Biochemistry 2001;34(3):173-82.

Neuman MG, Benhamou JP, Martinot M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clinical Biochemistry 1999;32(7):537-45.

Newsome PN, Beldon I, Moussa Y, et al. Low serum retinol levels are associated with hepatocellular carcinomain patients with chronic liver disease. Alimentary Pharmacology and Therapeutics 2000;14(10):1295-301.

Nguyen HA, Ho SB. Natural history of chronic hepatitis C: identifying a window of opportunity for intervention. Disease-a-Month 2001;47(12):593-609.

Ni YH, Chang GMH, Lin KH, et al. Hepatitis-C viral-infection in thalassemic children - clinical and molecular studies. Pediatr Res 1996;39(2):323-8.

Niederau C, Strohmery G, Heintges T, et al. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1998;45(21):797-804.

NIH Consensus Development Conference on Management of Hepatitis C: Bethesda, MD. Bethesda, MD: National Institutes of Health.

Ninomiya T, Yoon S, Hayashi Y, et al. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system. Journal of Gastroenterology and Hepatology 1998;13(1):68-74.

Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357(9251):196-7.

Nomura F, Ishijima M, Horikoshi A, et al. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. American Journal of Gastroenterology 1996;91(7):1380-3.

Nomura H, Kimura Y, Tada H, et al. Predictive factors of a response to interferon therapy in

chronic hepatitis-C. J Clin Gastroenterol 1996;23(3):185-90.

Nutt AK, Hassan HA, Lindsey J, et al. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels. American Journal of Medicine 2000;109(1):62-4.

O'Brien CB, Moonka DK, Henzel BS, et al. A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-alpha. American Journal of Gastroenterology 2001;96(8):2473-9.

O'Brien MJ, Keating NM, Elderiny S, et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 2000;114(5):712-8.

Ohashi Y. Changes of serum markers of hepatic fibrosis after interferon treatment of patients with chronic hepatitis C. Mie Medical Journal 1998;48(1-3):19-25.

Ohkawa K, Hayashi N, Yuki N, et al. Disease stage of chronic hepatitis C assessed by both peritoneoscopic and histologic findings and its relationship with response to interferon therapy. Gastrointestinal Endoscopy 1997;45(2):168-75.

Ohmiya M, Hayashi J, Ueno K, et al. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels. Digestive Diseases and Sciences 2000;45(10):1953-8.

Ohmori S, Shiraki K, Sugimoto K, et al. High expression of CD34-positive sinusoidal endothelial cells is a risk factor for hepatocellular carcinoma in patients with HCV-associated chronic liver diseases. Hum Pathol 2001;32(12):1363-70.

Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha -fetoprotein in cirrhotic patients monitored for developmenet of hepatocellular carcinoma. Hepatology 1994;19:61-6.

Okanoue T, Daimon Y, Kirishima T, et al. Retreatment with interferon-alpha at dosages or period increased by 1.3 times is effective for treatment for transient responders and non-responders in chronic hepatitis C patients. Hepatology Research 2001;20(3):348-58.

Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Journal of Hepatology 1999;30(4):653-9.

Okanoue T, Yasui K, Sakamoto S, et al. Circulating HCV-RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study. Liver 1996;16(4):241-7.

Ong JP, Younossi ZM, Speer C, et al. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001;21(4):266-71.

Ono E, Shiratori Y, Okudaira T, et al. Platelet count reflects stage of chronic hepatitis C. Hepatology Research 1999;15(3):192-200.

Onodera H, Ukai K, Suzuki M, et al. Incidence of hepatocellular carcinoma after interferon therapy in patients with chronic hepatitis C. Tohoku Exp Med 1997;181(2):275-83.

Ouzan D, Babany G, Valla D, et al. Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group. Journal of Viral Hepatitis 1998;5(1):53-9.

Ozdogan M, Ozgur O, Gur G, et al. Histopathological impacts of hepatitis virus infection in hemodialysis patients: should liver biopsy be performed before

renal transplantation? Artificial Organs 1997;21(5):355-8.

Papatheodoridis GV, Delladetsima JK, Katsoulidou A, et al. Significance of IgM anti-HCV core level in chronic hepatitis C. Journal of Hepatology 1997;27(1):36-41.

Paradis V, Mathurin P, Kollinger M, et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997;50(5):401-6.

Paradis V, Mathurin P, Laurent A, et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol 1996;49(12):998-1004.

Pardo M, Castillo I, Oliva H, et al. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 1997;26(5):1318-21.

Park GJ-H, Lin BPC, Ngu MC, et al. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?. Journal of Gastroenterology and Hepatology 2000;15(4):386-90.

Parking DM, Muir CS, Whelan SL, Gao Y-T, Ferlay J, Powell J. Cancer Incidence in Five Continents. 1994 World Health Statistics Annual (Vol 6) . Lyon IARC Scientific Publications. 117-129 World Healt Organization. Geneva WHO; 1995

Payen JL, Izopet J, Galindo-Migeot V, et al. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'etude et De Traitement du Virus De L'hepatite C (Get.Vhc). Hepatology 1998;28(6):1680-6.

Perez R, Pravia R, Artimez ML, et al. A comparison between two induction regimes for the interferon treatment of chronic hepatitis C. Response related factors. Revista Espanola De Enfermedades Digestivas 1997;89(3):167-73.

Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118(4):760-4.

Piccinino F, Felaco FM, Sagnelli E, et al. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment. Research in Virology 1998;149(5):283-91.

Plevris JN, Haydon GH, Simpson KJ, et al. Serum hyaluronan--a non-invasive test for diagnosing liver cirrhosis. European Journal of Gastroenterology and Hepatology 2000;12(10):1121-7.

Pockros PJ, Tong M, Lee WM, et al. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group. Journal of Viral Hepatitis 1998;5(4):271-6.

Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocomprimised patients. Journal of Hepatology 1998;29:12-9.

Poupon RE, Bonnand AM, Queneau PE, et al. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon. Scandinavian Journal of Gastroenterology 2000;35(6):642-9.

Poynard T, Bedossa P, BioulacSage P, et al. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. Journal of Viral Hepatitis 1997;4(3):199-208.

Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR,

CLINIVIR, and DOSVIRC groups. Lancet 1997;349(9055):825-32.

Poynard T, Daurat V, Chevret S, et al. A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group. Journal of Viral Hepatitis 1999;6(5):381-6.

Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138)1426-32.

Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. Journal of Hepatology 2001;34(5):730-9.

Prati D, Zanella A, Zanuso F, et al. Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. The Donor Surveillance Study Group. Journal of Viral Hepatitis 2000;7(5):352-60.

Punyagupta S, Jidpugdeebodin S, Siwadune T. Hepatitis C infection and hepatocellular carcinoma in Thailand: a long term study of 63 HCV patients. J Arch Infect Dis and Antimicrobial Agents 1999;16(1):1-5.

Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997;26(6):1393-8.

Puoti C, Stati T, Magrini A. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Liver 1999;19(2):104-9.

Puoti M, Cadeo G P, Putzolu V, et al. Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. Dig Liver Dis 2001;33(2):163-72.

Quan CM, Krajden M, Grigoriew GA, et al. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993;17(1):117-9.

Queneau PE, Osaer F, Bronowicki JP, et al. Treatment of mild chronic hepatitis C with interferon alpha-2b: results of a multi-centre randomized study in 80 patients. European Journal of Gastroenterology and Hepatology 2001;13(2):143-7.

Rabinovitz M, Block G, Finkelstein SD. Alpha-interferon retreatment of patients with chronic hepatitis C. American Journal of Gastroenterology 1996;91(8):1523-6.

Raedle J, Roth WK, Oremek G, et al. Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Digestive Diseases and Sciences 1995;40(12):2587-94.

Raymond RS, Fallon MB, Abrams GA. Oral thymic extract for chronic hepatitis C in patients previously treated with interferon. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1998;129(10):797-800.

Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30(3):787-93.

Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33(2):433-8.

Reichard O. Short-term versus sustained response to interferon therapy: effect on histology. Digestive

Diseases and Sciences 1996;41(12 SUPPL.):109S-14S.

Reichen J, Bianchi L, Buhler H, et al. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver. Journal of Hepatology 1996;25(3):275-82.

Resci G, Parisi G, Babnti S, et al. Chronic hepatitis-C - what treatment for nonresponsers to recombinant interferon-alpha. Clin Drug Invest 1996;11(4):224-8.

Ribavirin and chronic hepatitis C infection. FDA Consumer 2001;35(5):3.

Rodger AJ, Thomson JA, Thompson SC, et al. Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: results of a pilot study. Journal of Gastroenterology and Hepatology. 1999;14:269-73.

Rodrigues CM, Brites D, Serejo F, et al. Apoptotic cell death does not parallel other indicators of liver damage in chronic hepatitis C patients. Journal of Viral Hepatitis 2000;7(3):175-83.

Romeo R, Colombo M, Rumi M, et al. Lack of association between type of hepatitis C virus, serum load and severity of liver disease. Journal of Viral Hepatitis 1996;3(4):183-90.

Rossini A, Ravaggi A, Agostinelli E, et al. Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels. Liver 1997;17(3):133-8.

Rossini A, Ravaggi A, Biasi L, et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 1997;26(4):1012-7.

Rostaing L, Rumeau JL, Cisterne JM, et al. Liver histology in renal transplant patients after more than 10 years of hepatitis C virus infection. Transplantation Proceedings 1996;28(5):2836-7.

Rumi M, Del Ninno E, Parravicini ML, et al. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996;24(6):1366-70.

Rumi MG, Santagostino E, Morfini M, et al. A multicenter controlled, randomized, open trial of interferon alpha-2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997;89(10):3529-33.

Sachithanandan S, Clarke G, Crowe J, et al. Interferon-associated thyroid dysfunction in anti-D-related chronic hepatitis C. J Interferon Cytokine Res 1997;17(7):409-11.

Saito H, Ebinuma H, Atsukawa K, et al. Disappearance of serum hepatitis C virus RNA within two days after one dose interferon administration is predictive for response to high-dose interferon-alpha-2b treatment for chronic hepatitis C. Keio J Med 1997;46(2):74-80.

Saito H, Ebinuma H, Takahashi M, et al. Short-course of interferon-beta for the treatment of chronic hepatitis C: a multicenter trial for evaluating host immunological parameters. International Journal of Immunotherapy 1998;14(2):115-28.

Sakugawa H, Nakasone H, Kinjo F, et al. Clinical features of patients with chronic liver disease associated with hepatitis C virus genotype 1a/I in Okinawa, Japan. Journal of Gastroenterology and Hepatology 1997;12(2):176-81.

Salmeron FJ, Palacios A, Perezruiz M, et al. Epidemiology, serological markers, and hepatic-disease of anti-HCV ELISA-2-positive blood-donors. Digestive Diseases and Sciences 1996;41(10):1933-8.

Sanchez MG, Palacios A, Caballero T, et al. Efficacy of alpha 2b versus lymphoblastoid interferon in treatment of chronic hepatitis C. A randomized trial. Revista Espanola De Enfermedades Digestivas 1998;90(8):558-62.

Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. European Journal of Clinical Microbiology and Infectious Diseases 1995;14(11):949-53.

Sanchez-Tapias JM, Forms X, Ampurdanes S, et al. Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. Gut 1996;38(4):603-9.

Saracco G, Borghesio E, Mesina P, et al. Prolonged treatment (2 years) with different doses (3 versus 6 Mu) of interferon alpha-2b for chronic hepatitis type C: results of a multicenter randomized trial. Journal of Hepatology 1997;27(1):56-62.

Saracco G, Ciancio A, Ghisetti V, et al. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group. European Journal of Gastroenterology and Hepatology 2001;13(2):149-55.

Saracco G, Ciancio A, Olivero A, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001;34(1):133-8.

Sartori M, Andorno S, Rigamonti C, et al. Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis 2001;33(2):157-62.

Sassa T, Kumada T, Nakano S, et al. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 1999;11(12):1387-92.

Sata M, Fukuizumi K, Uchimura Y, et al. Hepatitis-C virus-infection in patients with clinically diagnosed alcoholic liver-diseases. Journal of Viral Hepatitis 1996;3(3):143-8.

Sata M, Ide T, Akiyoshi F, et al. Effects of interferon alpha2a on incidence of hepatocellular carcino main chronic active hepatitis without cirrhosis. Kurume Med J 1997;44(3):171-7.

Sato A, Kato Y, Nakata K, et al. Relationship between sustained elevation of serum alanine aminotranferase and progression from cirrhosis to hepatocellular-carinoma - comparison in patients with hepatits-B virus-associated and hepatitis C virus-associated cirrhosis. Journal of Gastroenterology and Hepatology 1996;11(10):944-8.

Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. New England Journal of Medicine 1993;328:1802-6.

Scheim OD, Friedman DS, Fleisher LA, et al. Anesthesia Management During Cataract Surgery. Evidence Report/Technology Assessment No. 16 (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-097-0006.) AHRQ Publication No. 01-E017. Rockville, MDAgency for Healthcare Research and Quality; 2001

Schroder O, Trojan J, Zeuzem S, et al. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 1998;37(8):279-85.

Schwetz BA. From the Food and Drug Administration. JAMA 2001;286(10):1166.

Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Annals of Internal Medicine 2000;132(2):105-11.

Seeff LB. Why is there such difficulty in defining the natural history of hepatitis C? Transfusion 2000;40(10):1161-4.

Serejo F, Costa A, Oliveira AG, et al. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III. Digestive Diseases and Sciences 2001;46(8):1684-9.

Serra MA, Ferrandez A, Gilabert MS, et al. Influence of pretreatment lesions on histologic response to interferon therapy in chronic hepatitis C. J Clin Gastroenterol 1998;26(4):296-9.

Sheehan MM, Doyle CT, Whelton M, et al. Hepatitis C virus liver disease in women infected with contaminated anti-D immunoglobulin. Histopathology 1997;30(6):512-7.

Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998;27(4):1128-35.

Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. American Journal of Gastroenterology 1998;93(1):44-8.

Shibata M, Morizane T, Uchida T, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998;351(9118):1773-7.

Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117(5):1164-72.

Shiffman ML, Hofmann CM, Gabbay J, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. American Journal of Gastroenterology 2000a;95(10):2928-35.

Sherman KE, Lewey SM, Goodman ZD. Talc in the liver of patients with chronic hepatitis C infection. American Journal of Gastroenterology 1995;90(12)2164-6.

Shiffman ML, Hofmann CM, Luketic VA, et al. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. Journal of Hepatology 1998;28(3):382-9.

Shiffman ML, Hofmann CM, Luketic VAC, et al. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology 1996;24(1):21-6.

Shiffman ML, Hofmann CM, Sterling RK, Luketic VA, Contos MJ, Sanyal AJ. A randomized controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response. 2001;184:405-9.

Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26(3):780-5.

Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000;182(6):1595-601.

Shima T, Tada H, Morimoto M, et al. Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. Journal of Gastroenterology and Hepatology 2000;15(3):294-9.

Shimizu I, Omoya T, Takaoka T, et al. Hepatitis C virus infection: clinical, virologic and pathologic features: serum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha -interferon therapy. Journal of Gastroenterology and Hepatology 2001;16(2):196-201.

Shindo M, Arai K, Okuno T. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. Journal of Hepatology 1997;26(3):492-7.

Shindo M, Hamada K, Oda Y, et al. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001;33(5):1299-302.

Shinzawa H, Yoshida Y, Masamune O, et al. Analysis of biochemical and virological efficacy of human lymphoblastoid interferon (IFN) in patients with compensated type C liver cirrhosis: comparative study between increase in individual IFN dose and prolonging of treatment period, using a multicenter randomized controlled trial. Digestive Diseases and Sciences 2000;45(3):575-80.

Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Annals of Internal Medicine 2000;132(7):517-24.

Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113(2):558-66.

Siciliano R, Carra R, Elia G, et al. Chronic hepatitis C in elderly patients: clinical, histological and virological features. Arch Gerontol Geriatr 1996;0(SUPPL. 5):327-33.

Silini E, Bottelli R, Asti M, et al. Hepatitis-C virus gentotypes and risk of hepatocellular-carcinoma in cirrhosis - a case-control study. Gastroenterology 1996;111(1):199-205.

Smith BC, Grove J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27(6):1695-9.

Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999;116(2):378-86.

Solmi L, Primerano AMM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular-carcinoma - results of a prospective study on 360 cases. American Journal of Gastroenterology 1996;91(6):1189-94.

Songsivilai S, Dharakul T, Senawong S. Hepatitis B- and hepatitis C-associated hepatocellular carcinoma: evaluation of alpha-fetoprotein as a diagnostic marker. Asian Pacific Journal of Allergy and Immunology 1995;13(2):167-71.

Soriano V, Bravo R, Garcia-Samaniego J, et al. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group. Journal of Infection 1997;35(3):225-30.

Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23(3):585-91.

Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the

natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. Journal of Hepatology 1997;26(1):1-5.

Stanley AJ, Haydon GH, Piris J, et al. Assessment of liver histology in patients with hepatitis-C and normal transaminiase levels. Eur J Clin Gastroenterol Hepatol 1996;8(9):869-72.

Suou T, Mitsuda A, Koda M, et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatology Research 2001;20(3):301-11.

Tabon M, Laudi C, Delmastro B, et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. Journal of Hepatology 2001;35(4):517-21.

Takano S, Yokosuka O, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-55.

Tamai T, Seki T, Shiro T, et al. Effects of alcohol consumption on histological changes in chronic hepatitis C: a clinicopathological study. Alcoholism, Clinical and Experimental Research 2000;24(4 Suppl):106S-11S.

Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. International Journal of Cancer 2000;87(5):741-9.

Tanaka K, Ikematsu H, Hirohata T, et al. Hepatitis-C virus-infection and risk of hepatocellular-carcinoma among Japanese - possible role of type 1B-(II) infection. J Nat Cancer Inst 1996;88(11):742-6.

Tappero G, Farina M, Negro F, et al. Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. Ital J Gastroenterol and Hepatology 1997;29(2):148-54.

Tassopoulos NC, Karvountzis G, Touloumi G, et al. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. American Journal of Gastroenterology 1996;91(9):1734-8.

Terranova R, Luca S. Preliminary results of beta-interferon treatment in the elderly. Control Clin Trials 1996;17(2):123-9.

Teuber G, Berg T, Naumann U, et al. Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. Journal of Viral Hepatitis 2001;8(4):276-83.

Thavarungkul P, Toriyama K, Kusuda M, et al. Clinico-pathological predictive factors of response to interferon therapy in chronic hepatitis C. Southeast Asian Journal of Tropical Medicine and Public Health 1996;27(1):85-90.

Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection. JAMA 2000;284(4):450-6.

Toccaceli F, Russo V, Rosati S, et al. Therapy of chronic hepatitis C with leukocyte interferon- alpha . Mediterranean Journal of Infectious and Parasitic Diseases 1996;11(1):33-9.

Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. Journal of Gastroenterology and Hepatology 2001;16(5):553-9.

Tong MJ, Elfarra NS. Clinical sequalae of hepatitis-C acquired from injection-drug use. West J Med 1996;164(5):399-404.

Tong MJ, Lai LP, MurakamiMori K. Development of hepatocellular carcinoma after clearance of

hepatitis C virus with interferon therapy. West J Med 1997;167(2):103-5.

Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology 1997;26(3):747-54.

Toyoda H, Kumada T, Nakano S, et al. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C. Oncology 2001;61(2):134-42.

Toyoda H, Nakano S, Kumada T, et al. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis-C. American Journal of Gastroenterology 1996;91(4):743-7.

Tradati F, Colombo M, Mannucci PM, et al. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998;91(4):1173-7.

Tran A, Longo F, Ouzan D, et al. Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity. Scandinavian Journal of Gastroenterology 2000;35(4):433-7.

Trevisani F, D'Intino PE, Caraceni P, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Cancer 1995;75:2220-32.

Tripi S, DiGaetano G, Soresi M, et al. Interferon-alpha alone versus interferon-alpha plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-alpha treatment. Biodrugs 2000;13(4):299-304.

Tsai J-F, Chang WY, Jeng JE, et al. Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer 1994;69(6):1157-9.

Tsai JF, Jeng JE, Chuang LY, et al. Urinary transforming growth factor beta(1) levels in hepatitis C virus-related chronic liver disease: correlation between high levels and severity of disease. Hepatology 1997;25(5):1141-6.

Tsai JF, Jeng JE, Chuang LY, et al. Clinical evaluation of urinary transforming growth factor-beta 1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br J Cancer 1997;75(10):1460-6.

Tsai JF, Jeng JE, Ho MS, et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997;76(7):968-74.

Tsai JF, Jeng JE, Ho MS, et al. Clinical evaluation of serum alpha-getoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma. Br J Cancer 1995;72:442-6.

Tsubota A, Kumada H, Arase Y, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. European Journal of Gastroenterology and Hepatology 1999;11(10):1077-83.

Tsubota A, Kumada H, Chayama K, et al. Relationship between pretreatment viermia level and response to interferon-alpha therapy in chronic hepatitis-C differs in viral type-1 and type-2 infections. Digestive Diseases and Sciences 1996;41(10):1925-32.

Tsushima H, Kawata S, Tamura S, et al. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. Journal of Hepatology 1999;30(1):1-7.

Tsuzurahara S, Sata M, Iwamoto O, et al. Detection of MAGE-4 protein in the sera of patients with hepatitis-C virus-associated hepatocellular carcinoma and liver cirrhosis. Japanese Journal of Cancer Research 1997;88(9):915-8.

Ueno T, Ide T, Hashimoto O, et al. Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers. Hepatogastroenterology 2001;48(40):1124-8.

Unoura M, Kaneko S, Matsushita E, et al. High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology 1993;40:305-10.

Utili R, Zampino R, Bellopede P, et al. Dual or single hepatitis B and C virus infections in childhood cancer survivors: long-term follow-up and effect of interferon treatment. Blood 1999;94(12):4046-52.

Valla DC, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29(6):1870-5.

van Rossum TG, Vulto AG, Hop WC, et al. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. Journal of Gastroenterology and Hepatology 1999;14(11):1093-9.

Van Thiel DH, Friedlander L, Molloy PJ, et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology 1996;43(12):1557-61.

Vandelli C, Renzo F, Braun HB, et al. Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C. Journal of Medical Virology 1999;58(1):26-34.

VanRoey G, Fevery J, VanSteenbergen W. Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Clin Gastroenterol Hepatol 2000;12(1):61-6.

Verbaan H, Bondeson L, Eriksson S. Non-invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection. Scandinavian Journal of Gastroenterology 1997;32(5):494-9.

Villa E, Grottola A, Buttafoco P, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. American Journal of Gastroenterology 2001;96(10):2973-7.

Villa E, Trande P, Grottola A, et al. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus: a prospective, double-blind, randomized study. Digestive Diseases and Sciences 1996;41(6):1241-7.

Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994;106(4)1000-5.

Wali M, Lewis S, Hubscher S, et al. Histological progression during short-term follow-up of patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis 1999;6(6):445-52.

Walsh KM, Fletcher A, MacSween RN, et al. Basement membrane peptides as markers of liver disease in chronic hepatitis C. Journal of Hepatology 2000;32(2):325-30.

Walsh KM, Fletcher A, MacSween RN, et al. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristic analysis. European Journal of Gastroenterology and Hepatology 1999;11(8):827-31.

Walsh KM, Timms P, Campbell S, et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Digestive Diseases and Sciences 1999a;44(3):624-30.

Weiss G, Umlauft F, Urbanek M, et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Arch Infect Dis 1999;180(5):1452-8.

Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48(3):378-83.

Wong VS, Baglin T, Beacham E, et al. The role for liver biopsy in haemophiliacs infected with the hepatitic virus. Br J Haematol 1997;97(2):343-7.

Wong VS, Hughes V, Trull A, et al. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. Journal of Viral Hepatitis 1998;5(3):187-92.

Wong VS, Wight DGD, Palmer CR, et al. Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model. J Clin Pathol 1996;49(6):465-9.

Yabuuchi I, Imai Y, Kawata S, et al. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 2000;20(4):290-5.

Yagura M, Murai S, Kojima H, et al. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method. Journal of Gastroenterology 2000;35(2):105-11.

Yagura M, Murai S, Kojima H, et al. Does the control of alanine aminotransferase levels lead to a regression of liver fibrosis in chronic hepatitis C patients? Hepatology Research 2001;19(2):144-57.

Yamada M, Fukuda Y, Koyama Y, et al. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 1996;11(7):646-51.

Yamada M, Fukuda Y, Nakano I, et al. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease. Acta Haematologica 1998;99(4):212-6.

Yamanaka N, Tanaka T, Tanaka W, et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997;79(8):1509-15.

Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23(6):1334-40.

Yao G, Ji Y, Yang M, et al. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients. Chinese Medical Journal 1998;111(10):922-6.

Yao GB, Fu XX, Tian GS, et al. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology 2000;15(10):1165-70.

Yao GB, Ji YY, Xu DZ, et al. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients. Hepatogastroenterology 1999;46(26):1059-64.

Yasunami R, Miyamoto T, Kanda T. HLA-DRB1 is related to the pathological changes of the liver in chronic hepatitis C. Hepatology Research 1997;7(1):3-12.

Yatsuhashi H, Yano M. Natural history of chronic hepatitis C. Journal of Gastroenterology and Hepatology 2000;15 Suppl:E111-6.

Yeo AET, Ghany M, Conry-Cantilena C, et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. Journal of Viral Hepatitis 2001;8(4):256-63.

Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Annals of Internal Medicine 1999;131(3):174-81.

Yoshimura E, Hayashi J, Kishihara Y, et al. Evaluation of quantitative assay for antibody to hepatitis-C virus score in patients treated with interferon. Digestive Diseases and Sciences 1996;41(1):155-60.

Yoshioka K, Yano M, Kusakabe A, et al. Randomized controlled trial of lymphoblastoid interferon alpha for chronic hepatitis C (comparison of 9-MU and 6-MU doses). IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine at Nagoya University School of Medicine. American Journal of Gastroenterology 1999;94(1):164-8.

Younossi ZM, Mullen KD, Zakko W, et al. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. Journal of Hepatology 2001;34(1):128-33.

Zardi EM, Toccaceli F, Russo V, et al. Chronic hepatitis C virus infection: detection of hepatocellular carcinoma by means of contrast-enhanced color doppler liver sonography. American Journal of Gastroenterology 2000;95(10):2996-8.

Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. Journal of Hepatology 1998;28(1):27-33.

Zarski JP, Maynard-Muet M, Chousterman S, et al. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology 1998;27(3):862-7.

Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. New England Journal of Medicine 2000a;343(23):1666-72.

Zeuzem S, Teuber G, Naumann U, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa-2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000;32(4 Pt 1):835-41.

Ziol M, Tran Van NJ, Roudot-Thoraval F, et al. A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C. Journal of Hepatology 1996;25(6):833-41.

Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. Journal of Hepatology 1999;30(2):185-91.